Canavese G, Catturich A, Vecchio C, Gipponi M, Tomei D, Sertoli M R, Repetto L, Badellino F
Division of Surgical Oncology, Università degli Studi, Genoa, Italy.
Eur J Surg Oncol. 1997 Feb;23(1):10-2. doi: 10.1016/s0748-7983(97)80135-7.
From May 1985 to June 1992, 375 patients were enrolled in a prospective controlled randomized clinical trial of peri-operative adjuvant chemotherapy (PAC) associated with long-term adjuvant chemo-endocrinotherapy in order to test the effectiveness of reducing the time interval between surgery and chemotherapy. The short-term surgical complications related to PAC are reported in order to verify whether such treatment might negatively affect the results of breast cancer surgery. One hundred and eighty-nine patients were randomly assigned to the peri-operative treatment, and 186 to the control group. Patients undergoing PAC received one course of cyclophosphamide (600 mg/sqm), epidoxorubicin (60 mg/ sqm), and 5-fluorouracil (600 mg/sqm) (CEF) within 48-72 h following surgery. Pathologically node-positive (N+) patients, who were given peri-operative CEF, had five further cycles of CEF alternated with six cycles of CMF (cyclophosphamide 600 mg/sqm, methotrexate 40 mg/sqm, and 5-fluorouracil 600 mg/sqm). All the other N+ patients received six cycles of CEF alternated with six cycles of CMF, starting within 30 days of surgery. No significant difference in post-operative morbidity was observed as regards median hospital stay (8 days), number of outpatient dressings (3.5 vs 3), seroma (51 (26.9%) vs 45 (24.2%)), lymphatic drainage (400 ml vs 409 ml), and post-operative infections, both local (10 vs 9) and in extraoperative foci (6 vs 7), in the study and control group, respectively. The toxicity of the peri-operative CEF was mainly gastrointestinal (nausea and vomiting, 55%; stomatitis, 3%), with only a small percentage (9%) reaching grades III-IV. Hair loss was the other main side effect (55%) with baldness in only 3%. Post-operative complications following radical breast cancer surgery seem to be primarily related to operative details (type of incision, accurate nerve-sparing technique, bleeding control, closure of subcutaneous and skin, drainage, aseptic technique) rather than to the one course of PAC.
1985年5月至1992年6月,375例患者参加了一项前瞻性对照随机临床试验,该试验涉及围手术期辅助化疗(PAC)与长期辅助化学内分泌治疗,以测试缩短手术与化疗时间间隔的有效性。报告了与PAC相关的短期手术并发症,以验证这种治疗是否可能对乳腺癌手术结果产生负面影响。189例患者被随机分配接受围手术期治疗,186例被分配到对照组。接受PAC的患者在手术后48 - 72小时内接受一个疗程的环磷酰胺(600 mg/平方米)、表柔比星(60 mg/平方米)和5-氟尿嘧啶(600 mg/平方米)(CEF)。接受围手术期CEF治疗的病理淋巴结阳性(N+)患者,再进行五个疗程的CEF,与六个疗程的CMF(环磷酰胺600 mg/平方米、甲氨蝶呤40 mg/平方米和5-氟尿嘧啶600 mg/平方米)交替进行。所有其他N+患者在手术后30天内开始接受六个疗程的CEF与六个疗程的CMF交替治疗。在中位住院时间(8天)、门诊换药次数(3.5次对3次)、血清肿(51例(26.9%)对45例(24.2%))、淋巴引流(400毫升对409毫升)以及术后感染方面,无论是局部感染(10例对9例)还是手术外病灶感染(6例对7例),研究组和对照组均未观察到术后发病率的显著差异。围手术期CEF的毒性主要为胃肠道反应(恶心和呕吐,55%;口腔炎,3%),只有小部分(9%)达到III - IV级。脱发是另一个主要副作用(55%),仅有3%出现秃头。乳腺癌根治术后的并发症似乎主要与手术细节(切口类型、精确的神经保留技术、出血控制、皮下和皮肤缝合、引流、无菌技术)有关,而非与一个疗程的PAC有关。